The producer of the revolutionary device supporting breast cancer diagnostics is continuously increasing the availability of its product in key pharmacies throughout the country. At present, you can buy Braster in more than 494 pharmacies belonging to the largest Polish chains, such as: Dr Zdrowie, Amica, MaxFarm, Wracam do Zdrowia, Cefarm, Zdrowit and Apteka Bliska. In selected pharmacies you can find promotional materials and the device itself is visibly put on a dedicated point-of-sale display.

Braster was placed on the market on October 19. First, it was available via the Company’s online store, which allows the Company to maximise the margins. The first chain of pharmacies to offer the device was Dr Zdrowie. Currently, Braster is available in almost 500 pharmacies throughout the country. BRASTER hired experienced salespersons responsible for educating pharmacy personnel to provide quality service to women interested in the product.

"On the Polish market, our own online store and the chains of pharmacies will serve as our main distribution channels. Cooperation with further chains of pharmacies will let us increase our customer outreach. New contracts are still at the negotiation stage," explains Marcin Halicki, President of the Management Board of BRASTER S.A.

The Company’s sales strategy envisages that the total price is made up of the cost of the device and a 24-month subscription under three price options. The first option includes no initial (nominal) payment and a monthly subscription fee of PLN 45 for 24 months. The second option includes an initial payment for the Braster device of PLN 195 and a monthly subscription fee of PLN 29 for 24 months. The third option provides for a one-off payment of PLN 891 for the device and the access the service for 24 months.

The technologies developed by the Polish scientists and used in the Braster device are subject to patent protection in Poland and in 45 other countries worldwide. At present, the Company is focusing on the promotional campaign in the country. At the same time, the Company is finalising its sales strategy on the foreign markets. The product is to be placed on one of the chosen European markets under a pilot project at the beginning of the next year. The international commercialisation of the product will start to generate considerable revenues, which will strategically influence the future financial results.